12 / 38
Median PFS, months (95% CI)
18.9 (15.2, 21.4)
10.2 (9.6, 11.1)
1.0
Probability of progression-free survival
0.2
0.4
0.6
0.8
0.0
0
3
6
9
12
15
18
21
24
27
Time from randomisation (months)
279
277
262
239
233
197
210
152
178
107
139
78
71
37
26
10
4
2
0
0
No. at risk
Osimertinib
SoC
Osimertinib
SoC
FLAURA: PFS by investigator assessment
Tick marks indicate censored data;
342 events in 556 patients at DCO: 62% maturity; osimertinib: 136 events (49%), SoC: 206 events (74%)
HR 0.46
(95% CI 0.37, 0.57)
p<0.0001
Ramalingam et al ESMO 2017 #LBA2; Soria NEJM 2017